ASLAN Pharmaceuticals Submits Clinical Trial Authorisation Application for First in Man Studies for ASLAN004
July 03, 2018 04:01 ET | ASLAN Pharmaceuticals Limited
SINGAPORE, July 03, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT) (NASDAQ:ASLN), a clinical-stage biopharmaceutical company based in Asia developing novel therapeutics for global...
ASLAN Pharmaceuticals to Present Two Posters on Varlitinib at ASCO
May 17, 2018 02:25 ET | ASLAN Pharmaceuticals Limited
SINGAPORE, May 17, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT) (Nasdaq:ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia...
ASLAN Pharmaceuticals Prices Initial Public Offering of Its American Depositary Shares
May 04, 2018 10:59 ET | ASLAN Pharmaceuticals Limited
SINGAPORE, May 04, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Limited (TPEx:6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals Announces Presentation of New Pre-Clinical Data on Varlitinib in Hepatocellular Carcinoma at AACR
April 17, 2018 09:30 ET | ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, April 17, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN) (6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
Aslan Pharmaceuticals Files for Proposed Initial Public Offering in the U.S.
March 26, 2018 21:00 ET | ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, March 26, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN) (6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
ASLAN Pharmaceuticals Sponsors Cholangiocarcinoma Foundation Annual Conference 2018
January 31, 2018 01:00 ET | ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Jan. 31, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN) (6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
ASLAN Pharmaceuticals Appoints Stephen Doyle as Head of China
January 18, 2018 01:00 ET | ASLAN Pharmaceuticals
SINGAPORE , Jan. 18, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
ASLAN Pharmaceuticals Announces Shortened Timeline to Commercialisation for Varlitinib in China
January 08, 2018 01:00 ET | ASLAN Pharmaceuticals
SINGAPORE, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
ASLAN Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
January 04, 2018 02:00 ET | ASLAN Pharmaceuticals
SINGAPORE, Jan. 04, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for Varlitinib From Array BioPharma
January 03, 2018 03:00 ET | ASLAN Pharmaceuticals
SINGAPORE, Jan. 03, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...